Atossa Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview

Atossa Therapeutics

08/11/2024 15:53

* Atossa Therapeutics Inc  ATOS.OQ   ATOS.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 11 (estimated) for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Atossa Therapeutics Inc
is for
a loss of 6 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Atossa
Therapeutics Inc is 6.00​, above​ its last closing price
of $1.50. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.06       -0.06      -0.05     Beat    11.8
 Mar. 31 2024  -0.07       -0.07      -0.05     Beat    25
 Jan. 1 0001   -0.05       -0.06      -0.09     Missed  -58.8​
 Sep. 30 2023  -0.07       -0.07      -0.05     Beat    28.6
 ​​Jun.                    -0.06      -0.08     Missed  -33.3
 30 2023                                                
 Mar. 31 2023              -0.06      -0.05     Beat    16.7​
 Jan. 1 0001               -0.06      -0.06     Met     0
 Jan. 1 0001               -0.06      -0.06     Met     0
 This summary was machine generated November 8 at 15:52 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)